EUCTR2014-005724-10-GB进行中（未招募）1 期
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Reduced Ejection Fraction
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Willing and able to provide signed informed consent form (ICF) prior to participation in any study-related procedures.
- •2. Age =40 and =80 years.
- •3. A known history of chronic ischemic or non-ischemic cardiomyopathy of at least 6 months duration from the time of the initial diagnosis, or signs and symptoms consistent with heart failure.
- •4. Receiving heart failure (HF) treatment, including, but not limited to, angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB), and an evidence-based beta blocker for the treatment of HF. Subjects who cannot tolerate ACEI or ARB due to reduced renal function or hypotension are eligible. Subjects may be receiving aldosterone antagonists, but this is not a requirement for the study.
- •5. HF is considered to be stable in the judgment of the Investigator AND doses of HF treatment have been stable for at least 1 month prior to the Screening Visit.
- •6. In normal sinus rhythm (electrocardiogram documented) at Screening and Day 1 and no history of atrial fibrillation in the past 12 months
- •7. No hospitalization related to HF within 1 month prior to the Screening Visit.
- •8. Left Ventricular Ejection Fraction (LVEF) = 40% by 2-D echocardiography at Screening.
- •9. At least 3 viable segments (hyperenhancement = 25%) by a qualifying delayed gadolinium-enhanced cardiac MRI examination at Screening (confirmed by independent core lab).
- •10. Willing to adhere to the study requirements for the length of the trial.
- •11. Women of childbearing potential must agree to use 1 of the following methods of birth control from the date they sign the ICF until two months after the last dose of study medication:
- •a. Abstinence, when it is in line with the preferred and usual lifestyle of the subject. Subject agrees to use an acceptable method of contraception should they become sexually active.
- •b. Maintenance of monogamous relationship with a male partner who has been surgically sterilized by vasectomy (the vasectomy procedure must have been conducted at least 60 days prior to the Screening Visit or confirmed via sperm analysis).
- •c. Barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine device or system.
- •Note: Non-childbearing potential is defined as surgical sterilization (e.g., bilateral oophorectomy, hysterectomy, or tubal ligation) or postmenopausal (defined as permanent cessation of menstruation for at least 12 consecutive months prior to the Screening Visit).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. History of any concurrent medical condition which, in the opinion of the Investigator, significantly increases the potential risks associated with administration of study medication or any other aspect of study participation.
- •2. Any contraindication to MRI scanning as assessed by local MRI safety questionnaire, which may include:
- •a. History of intra-orbital metal fragments which have not been removed
- •b. Severe claustrophobia
- •c. Non-MRI safe cochlear implant(s) or intracranial aneurysm clips
- •d. Extensive tattoos located on the torso that contain metallic inks
- •e. Other non-removable implanted metallic or electronic devices that have not been determined to be MRI safe
- •f. Inability to lie flat
- •3. Inadequate echocardiogram image quality (defined as poor sound transmission and/or < 10 endocardial segments seen).
- •4. LVEDD indexed to Body Surface Area is > 45 mm/m2 assessed by 2-D echocardiography.
- •5. Coronary or peripheral revascularization procedures, valvular procedures, OR any major surgical procedure within 3 months prior to the Screening Visit.
- •6. Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 3 months prior to the Screening Visit.
- •7. Obstructive or restrictive cardiomyopathy, infiltrative diseases of the myocardium (e.g., amyloid, sarcoid, etc.) myocarditis, or reductions in LV function thought to be secondary primarily to valvular heart disease, prior cardiac valve surgery or known aortic stenosis.
- •8. The presence or anticipated placement of any pacemaker, implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) devices during the ensuing 6-week study period.
- •9. Presence of second degree or advanced heart block.
- •10. Uncontrolled hypertension defined as a systolic blood pressure > 160 mmHg or a diastolic blood pressure > 110 mmHg on at least two consecutive readings.
- •11. Presence of any left ventricular thrombus, pericardial disease, uncorrected thyroid disease or a dyskinetic left ventricular aneurysm.
- •12. History of cancer that causes symptoms, disabilities, or is likely to lead to hospitalization or treatment in the next 12 months.
- •13. Currently receiving treatment with chemotherapeutic agents or immunosuppressant agents or has received prior radiation therapy to the chest.
- •14. Liver enzymes (alanine aminotransferase [ALT] AND/OR aspartate aminotransferase[AST]) elevation > 3 times the upper limit of normal (ULN).
- •15. Total bilirubin > 1.5 times ULN in the absence of Gilbert’s Syndrome.
- •16. Bleeding diathesis or any known blood dyscrasia.
- •17. Anemia, defined as hemoglobin < 9 g/dL or planned blood transfusions in the next 6 weeks.
- •18. Estimated glomerular filtration rate (eGFR) < 30 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation:
- •eGFR (mL/min/1.73 m2) = 175 x (Scr)^[-1.154] x (Age)^[-0.203] x (0.742 if female) x (1.212 if African American)
- •19. History of hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection, or diagnosis of immunodeficiency.
- •20. Known active drug or alcohol abuse within 1 year of the
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Preserved Ejection FractioHeart failure with preserved ejection fraction (HFpEF)EUCTR2015-005615-32-DEStealth BioTherapeutics Inc.46
已完成
2 期
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Reduced Ejection FractioStable Heartfailure10019280NL-OMON45900Stealth BioTherapeutics Inc.25
进行中（未招募）
1 期
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Reduced Ejection FractioStable Heart Failure with Reduced Ejection FractionMedDRA version: 19.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2014-005724-10-NLStealth BioTherapeutics Inc.70
进行中（未招募）
1 期
The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with Gemcitabine. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma when it is given with Gemcitabine. Gemcitabine is approved by the FDA for metastatic pancreatic adenocarcinoma.Metastatic Pancreatic AdenocarcinomaMedDRA version: 15.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2011-003753-26-PLGilead Sciences, Inc.244
进行中（未招募）
不适用
The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with Gemcitabine. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma when it is given with Gemcitabine. Gemcitabine is approved by the FDA for metastatic pancreatic adenocarcinoma.Metastatic Pancreatic AdenocarcinomaMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2011-003753-26-DEGilead Sciences, Inc.244